In CRC, T-DXd has demonstrated activity in patients with HER2-expressing refractory metastatic CRC in the phase II trial DESTINY-CRC01, with an ORR of 45% and a disease control rate (DCR) of 83% [19]. The gene discussed is ERBB2; the disease is colorectal carcinoma.